Endocarditis Following Ocrelizumab in Relapsing-Remitting MS

Neurology: Neuroimmunology and NeuroInflammation - United States
doi 10.1212/nxi.0000000000000680
Full Text
Abstract

Available in full text

Categories
Neurology
Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Ocrelizumab for Relapsing or Primary Progressive MS

Prescriber
Pharmacology
2018English

Natalizumab for Relapsing-Remitting Ms in the Uk Top Cohort

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
2014English

Acute Effects of Alemtuzumab Infusion in Patients With Active Relapsing-Remitting MS

Neurology: Neuroimmunology and NeuroInflammation
Neurology
2016English

Intestinal Permeability in Relapsing-Remitting Multiple Sclerosis

Neurotherapeutics
NeurologyPharmacology
2017English

Disease-Modifying Therapies in Relapsing–remitting Multiple Sclerosis

Neuropsychiatric Disease and Treatment
PsychiatryMental HealthBiological Psychiatry
2010English

Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis

Archives of Neurology
2009English

Stressful Events Increase Exacerbations in Relapsing-Remitting Multiple Sclerosis

BMJ
2003English

Cerebrovascular Reactivity and Disease Activity in Relapsing-Remitting Multiple Sclerosis

Advances in Clinical and Experimental Medicine
BiochemistryMedicineGeneticsMolecular Biology
2020English

Treatment of Remitting-Relapsing Multiple Sclerosis (MS) With Cladribine: Results of an Open Pilot Study at 18 Months

Journal of Neurology
Neurology
1996English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy